Join
Akouos Inc. logo

AKUS

NASDAQ

Akouos Inc.

SectorConsumer DiscretionaryIndustrySpecialty ChemicalsIPO2020
$13.29+0.14 (+1.10%)
News25/Ratings1

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. Akouos, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

Latest news

25 items

AKUS FAQ

7 questions
  • What does Akouos Inc. do?
    Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic...
  • Where does AKUS stock trade?
    Akouos Inc. (AKUS) is listed on NASDAQ.
  • What sector and industry is AKUS in?
    Akouos Inc. operates in the Consumer Discretionary sector, Specialty Chemicals industry.
  • When did Akouos Inc. go public?
    Akouos Inc. (AKUS) completed its IPO in 2020.
  • What are analysts saying about AKUS?
    Akouos Inc. has had 1 recent analyst action on file. The most recent action was from William Blair: Outperform with a $1200.00 price target on 2022-09-29. Recent price targets cluster around $1200.00.
  • What companies are similar to AKUS?
    Notable peers in the same industry include STOK (Stoke Therapeutics Inc.), VOR (Vor Biopharma Inc.), DBTX (Decibel Therapeutics Inc.). Compare AKUS side-by-side with any of them on Quantisnow.
  • How can I track AKUS on Quantisnow?
    Quantisnow aggregates Akouos Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AKUS to receive live email and push alerts on every new disclosure.